Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate

Antioxidants and Redox Signaling

Volumn 26, Issue 14, 2017, Pages 748-762

  Belcher, John D ^a   Chen, Chunsheng ^a   Nguyen, Julia ^a   Zhang, Ping ^a   Abdulla, Fuad ^a   Nguyen, Phong ^a   Killeen, Trevor ^a   Xu, Pauline ^a   O'Sullivan, Gerry ^b   Nath, Karl A ^c   Vercellotti, Gregory M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

haptoglobin; hemopexin; HO 1; Nrf2; sickle cell disease

Indexed keywords

CELL ADHESION MOLECULE; CYTOPROTECTIVE AGENT; FERRITIN; FUMARIC ACID DIMETHYL ESTER; HAPTOGLOBIN; HEME; HEME OXYGENASE 1; HEMOGLOBIN F; HEMOPEXIN; LACTATE DEHYDROGENASE; MESSENGER RNA; METHYLCELLULOSE; PROTOPORPHYRIN TIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR RELA; NFE2L2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; LIVER NECROSIS; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RETICULOCYTE COUNT; SICKLE CELL ANEMIA; SPLEEN WEIGHT; ANIMAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; INFLAMMATION; METABOLISM; ORAL DRUG ADMINISTRATION; TRANSGENIC MOUSE;

ADMINISTRATION, ORAL; ANEMIA, SICKLE CELL; ANIMALS; DIMETHYL FUMARATE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INFLAMMATION; MALE; MICE; MICE, TRANSGENIC; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS;

EID: 85018976715     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2015.6571     Document Type: Article

References (65)

1. Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A, Kovacs Z, Lewerenz J, Lisak D, Maher P, Mausberg AK, Quasthoff K, Zimmermann C, Hartung HP, and Methner A. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation 9: 163, 2012.
2. Balla G, Vercellotti GM, Muller-Eberhard U, Eaton J, and Jacob HS. Exposure of endothelial cells to free heme potentiates damage mediated by granulocytes and toxic oxygen species. Lab Invest 64: 648-655, 1991.
3. Barnard ML, Muller-Eberhard U, and Turrens JF. Protective role of hemopexin on heme-dependent lung oxidative stress. Biochem Biophys Res Commun 192: 82-87, 1993.
4. Bean CJ, Boulet SL, Ellingsen D, Pyle ME, Barron-Casella EA, Casella JF, Payne AB, Driggers J, Trau HA, Yang G, Jones K, Ofori-Acquah SF, Hooper WC, and De Baun MR. Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease. Blood 120: 3822-3828, 2012.
5. Belcher JD, Chen C, Nguyen J, Milbauer L, Abdulla F, Alayash AI, Smith A, Nath KA, Hebbel RP, and Vercellotti GM. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 123: 377-390, 2014.
6. Belcher JD, Mahaseth H, Welch TE, Otterbein LE, Hebbel RP, and Vercellotti GM. Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle mice. J Clin Invest 116: 808-816, 2006.
7. Belcher JD, Nath KA, and Vercellotti GM. Vasculotoxic and pro-inflammatory effects of plasma heme: cell signaling and cytoprotective responses. ISRN Oxid Med 2013: Article ID 831596, 2013.
8. Belcher JD, Nguyen J, Chen C, Abdulla F, Nguyen P, Nguyen M, Zhang P, Xu P, Slipek NJ, and Vercellotti, GM. Dimethyl fumarate induces cytoprotection and inhibits vaso-occlusion in transgenic sickle mice. Am Soc Hematol 124: 219, 2014.
9. Belcher JD, Vineyard JV, Bruzzone CM, Chen C, Beckman JD, Nguyen J, Steer CJ, and Vercellotti GM. Heme oxygenase-1 gene delivery by Sleeping Beauty inhibits vascular stasis in a murine model of sickle cell disease. J Mol Med (Berl) 88: 665-675, 2010.
10. Belcher JD, Young M, Chen C, Nguyen J, Burhop K, Tran P, and Vercellotti GM. MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice. Blood 122: 2757-2764, 2013.
11. Boretti FS, Buehler PW, D'Agnillo F, Kluge K, Glaus T, Butt OI, Jia Y, Goede J, Pereira CP, Maggiorini M, Schoedon G, Alayash AI, and Schaer DJ. Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs. J Clin Invest 119: 2271-2280, 2009.
12. Boyle JJ, Johns M, Lo J, Chiodini A, Ambrose N, Evans PC, Mason JC, and Haskard DO. Heme induces heme oxygenase 1 via Nrf2: role in the homeostatic macrophage response to intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 31: 2685-2691, 2011.
13. Camus SM, De Moraes JA, Bonnin P, Abbyad P, Le Jeune S, Lionnet F, Loufrani L, Grimaud L, Lambry JC, Charue D, Kiger L, Renard JM, Larroque C, Le Clesiau H, Tedgui A, Bruneval P, Barja-Fidalgo C, Alexandrou A, Tharaux PL, Boulanger CM, and Blanc-Brude OP. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood 125: 3805-3814, 2015.
14. Chorley BN, Campbell MR, Wang X, Karaca M, Sambandan D, Bangura F, Xue P, Pi J, Kleeberger SR, and Bell DA. Identification of novel NRF2-regulated genes by ChIPSeq: influence on retinoid X receptor alpha. Nucleic Acids Res 40: 7416-7429, 2012.
15. Duffy S, So A, and Murphy TH. Activation of endogenous antioxidant defenses in neuronal cells prevents free radicalmediated damage. J Neurochem 71: 69-77, 1998.
16. Durand RE and Olive PL. Flow cytometry techniques for studying cellular thiols. Radiat Res 95: 456-470, 1983.
17. Fabry ME, Nagel RL, Pachnis A, Suzuka SM, and Costantini F. High expression of human beta S-and alphaglobins in transgenic mice: hemoglobin composition and hematological consequences. Proc Natl Acad Sci U S A 89: 12150-12154, 1992.
18. Fairbanks VF, Ziesmer SC, and O'Brien PC. Methods for measuring plasma hemoglobin in micromolar concentration compared. Clin Chem 38: 132-140, 1992.
19. Fang J, Qin H, Seki T, Nakamura H, Tsukigawa K, Shin T, and Maeda H. Therapeutic potential of pegylated hemin for reactive oxygen species-related diseases via induction of heme oxygenase-1: results from a rat hepatic ischemia/reperfusion injury model. J Pharmacol Exp Ther 339: 779-789, 2011.
20. Foresti R, Bains SK, Pitchumony TS, de Castro Bras LE, Drago F, Dubois-Rande JL, Bucolo C, and Motterlini R. Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells. Pharmacol Res 76: 132-148, 2013.
21. Frycak P, Zdrahal Z, Ulrichova J, Wiegrebe W, and Lemr K. Evidence of covalent interaction of fumaric acid esters with sulfhydryl groups in peptides. J Mass Spectrom 40: 1309-1318, 2005.
22. Ghosh S, Adisa OA, Chappa P, Tan F, Jackson KA, Archer DR, and Ofori-Acquah SF. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest 123: 4809-4820, 2013.
23. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, and Dawson KT. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367: 1098-1107, 2012.
24. Held KD, Epp ER, Clark EP, and Biaglow JE. Effect of dimethyl fumarate on the radiation sensitivity of mammalian cells in vitro. Radiat Res 115: 495-502, 1988.
25. Hunt RC, Hunt DM, Gaur N, and Smith A. Hemopexin in the human retina: protection of the retina against hememediated toxicity. J Cell Physiol 168: 71-80, 1996.
26. Hvidberg V, Maniecki MB, Jacobsen C, Hojrup P, Moller HJ, and Moestrup SK. Identification of the receptor scavenging hemopexin-heme complexes. Blood 106: 2572-2579, 2005.
27. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S, and Yamamoto M. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 275: 16023-16029, 2000.
28. Jison ML, Munson PJ, Barb JJ, Suffredini AF, Talwar S, Logun C, Raghavachari N, Beigel JH, Shelhamer JH, Danner RL, and Gladwin MT. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood 104: 270-280, 2004.
29. Kalambur VS, Mahaseth H, Bischof JC, Kielbik MC, Welch TE, Vilback A, Swanlund DJ, Hebbel RP, Belcher JD, and Vercellotti GM. Microvascular blood flow and stasis in transgenic sickle mice: utility of a dorsal skin fold chamber for intravital microscopy. Am J Hematol 77: 117-125, 2004.
30. Kato GJ. Haptoglobin halts hemoglobin's havoc. J Clin Invest 119: 2140-2142, 2009.
31. Keleku-Lukwete N, Suzuki M, Otsuki A, Tsuchida K, Katayama S, Hayashi M, Naganuma E, Moriguchi T, Tanabe O, Engel JD, Imaizumi M, and Yamamoto M. Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation. Proc Natl Acad Sci U S A 112: 12169-12174, 2015.
32. Kleihauer E, Braun H, and Betke K. [Demonstration of fetal hemoglobin in erythrocytes of a blood smear]. Klin Wochenschr 35: 637-638, 1957.
33. Lanaro C, Franco-Penteado CF, Albuqueque DM, Saad ST, Conran N, and Costa FF. Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy. J Leukoc Biol 85: 235-242, 2009.
34. Li RC, Saleem S, Zhen G, Cao W, Zhuang H, Lee J, Smith A, Altruda F, Tolosano E, and Dore S. Heme-hemopexin complex attenuates neuronal cell death and stroke damage. J Cereb Blood Flow Metab 29: 953-964, 2009.
35. Lin SX, Lisi L, Dello Russo C, Polak PE, Sharp A, Weinberg G, Kalinin S, and Feinstein DL. The antiinflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro 3: pii: e00055, 2011.
36. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G, Bruck W, Dawson K, Goelz S, Wiese S, Scannevin RH, Lukashev M, and Gold R. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134: 678-692, 2011.
37. Lynch EC. Peripheral blood smear. In: Clinical Methods: The History, Physical, and Laboratory Examinations, edited by Walker HK, Hall WD, and Hurst JW. Boston: Butterworths, 1990, pp. 732-734.
38. Macari ER and Lowrey CH. Induction of human fetal hemoglobin via the NRF2 antioxidant response signaling pathway. Blood 117: 5987-5997, 2011.
39. Mollan TL, Jia Y, Banerjee S, Wu G, Kreulen RT, Tsai AL, Olson JS, Crumbliss AL, and Alayash AI. Redox properties of human hemoglobin in complex with fractionated dimeric and polymeric human haptoglobin. Free Radic Biol Med 69: 265-277, 2014.
40. Muller-Eberhard U. [47] Hemopexin. In: Methods in Enzymology, edited by Di Sabato G. Academic Press: Orlando, Florida, 1988, pp. 536-565.
41. Muller-Eberhard U, Javid J, Liem HH, Hanstein A, and Hanna M. Plasma concentrations of hemopexin, haptoglobin and heme in patients with various hemolytic diseases. Blood 32: 811-815, 1968.
42. Murphy TH, Yu J, Ng R, Johnson DA, Shen H, Honey CR, and Johnson JA. Preferential expression of antioxidant response element mediated gene expression in astrocytes. J Neurochem 76: 1670-1678, 2001.
43. Nath KA, Grande JP, Haggard JJ, Croatt AJ, Katusic ZS, Solovey A, and Hebbel RP. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. Am J Pathol 158: 893-903, 2001.
44. Niture SK, Khatri R, and Jaiswal AK. Regulation of Nrf2-an update. Free Radic Biol Med 66: 36-44, 2014.
45. Nouraie M, Lee JS, Zhang Y, Kanias T, Zhao X, Xiong Z, Oriss TB, Zeng Q, Kato GJ, Gibbs JS, Hildesheim ME, Sachdev V, Barst RJ, Machado RF, Hassell KL, Little JA, Schraufnagel DE, Krishnamurti L, Novelli E, Girgis RE, Morris CR, Rosenzweig EB, Badesch DB, Lanzkron S, Castro OL, Goldsmith JC, Gordeuk VR, and Gladwin MT. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica 98: 464-472, 2013.
46. Promsote W, Makala L, Li B, Smith SB, Singh N, Ganapathy V, Pace BS, and Martin PM. Monomethylfumarate induces gamma-globin expression and fetal hemoglobin production in cultured human retinal pigment epithelial (RPE) and erythroid cells, and in intact retina. Invest Ophthalmol Vis Sci 55: 5382-5393, 2014.
47. Reagan-Shaw S, Nihal M, and Ahmad N. Dose translation from animal to human studies revisited. FASEB J 22: 659-661, 2008.
48. Scannevin RH, Chollate S, Jung MY, Shackett M, Patel H, Bista P, Zeng W, Ryan S, Yamamoto M, Lukashev M, and Rhodes KJ. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 341: 274-284, 2012.
49. Schaer DJ, Buehler PW, Alayash AI, Belcher JD, and Vercellotti GM. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 121: 1276-1284, 2013.
50. Shen G, Xu C, Hu R, Jain MR, Gopalkrishnan A, Nair S, Huang MT, Chan JY, and Kong AN. Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. Mol Cancer Ther 5: 39-51, 2006.
51. Singh S, Vrishni S, Singh BK, Rahman I, and Kakkar P. Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radic Res 44: 1267-1288, 2010.
52. Spencer SR, Wilczak CA, and Talalay P. Induction of glutathione transferases and NAD(P)H:quinone reductase by fumaric acid derivatives in rodent cells and tissues. Cancer Res 50: 7871-7875, 1990.
53. Steinberg MH, Chui DH, Dover GJ, Sebastiani P, and Alsultan A. Fetal hemoglobin in sickle cell anemia: a glass half full? Blood 123: 481-485, 2014.
54. Takaya K, Suzuki T, Motohashi H, Onodera K, Satomi S, Kensler TW, and Yamamoto M. Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Free Radic Biol Med 53: 817-827, 2012.
55. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, and Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 62: 5196-5203, 2002.
56. Tolosano E, Fagoonee S, Morello N, Vinchi F, and Fiorito V. Heme scavenging and the other facets of hemopexin. Antioxid Redox Signal 12: 305-320, 2010.
57. Tsuji Y, Ayaki H, Whitman SP, Morrow CS, Torti SV, and Torti FM. Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol Cell Biol 20: 5818-5827, 2000.
58. Vercellotti GM, Khan FB, Nguyen J, Chen C, Bruzzone CM, Bechtel H, Brown G, Nath KA, Steer CJ, Hebbel RP, and Belcher JD. H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice. Front Pharmacol 5: 79, 2014.
59. Vercellotti GM, Zhang P, Chen C, Nguyen J, Abdulla F, Nguyen P, Nowotny C, Irfnullah A, Smith A, Steer CJ, and Belcher JD. Hemopexin gene therapy inhibits inflammation and vaso-occlusion in transgenic sickle cell mice. In: American Society of Hematology Annual Meeting & Exposition. Orlando, FL: ASH, 2015, p. 412.
60. Vinchi F, De Franceschi L, Ghigo A, Townes T, Cimino J, Silengo L, Hirsch E, Altruda F, and Tolosano E. Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases. Circulation 127: 1317-1329, 2013.
61. Vinchi F, Gastaldi S, Silengo L, Altruda F, and Tolosano E. Hemopexin prevents endothelial damage and liver congestion in a mouse model of heme overload. Am J Pathol 173: 289-299, 2008.
62. Walsh J, Jenkins RE, Wong M, Olayanju A, Powell H, Copple I, O'Neill PM, Goldring CE, Kitteringham NR, and Park BK. Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implications. J Proteomics 108: 171-187, 2014.
63. Wang Y, Santa-Cruz K, De Carli C, and Johnson JA. NAD(P)H:quinone oxidoreductase activity is increased in hippocampal pyramidal neurons of patients with Aalzheimer's disease. Neurobiol Aging 21: 525-531, 2000.
64. Wasserman WW and Fahl WE. Functional antioxidant responsive elements. Proc Natl Acad Sci U S A 94: 5361-5366, 1997.
65. Wu LC, Sun CW, Ryan TM, Pawlik KM, Ren J, and Townes TM. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 108: 1183-1188, 2006.